Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

Inclusion Criteria: * Healthy infants at least 6 weeks (42 days) and up to 12 weeks (84 days) of age at the time of the first study vaccination * Parent/legal guardian agrees to participate by giving written informed consent and is willing and able to comply with study requirements Exclusion Criteria: * History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic diarrhea, failure to thrive, or abdominal surgery * History of intussusception * Impairment of immunological function, including Severe Combined Immunodeficiency (SCID) * Acute disease, severe chronic disease, or chronic disease during the acute period * Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological disease * Hypersensitivity to any component of the rotavirus vaccine, OPV, or DTaP * Prior receipt of any rotavirus vaccine * Fever, with an axillary temperature \>=37.5 °C (or equivalent) within 24 hours before study vaccination (study vaccination can be deferred until complete resolution of febrile illness) * Clinical evidence of active gastrointestinal illness * Received intramuscular, oral, or intravenous corticosteroid treatment since birth (topical, ophthalmic, and inhaled steroids are permitted) * Resides in a household with an immunocompromised person * Receipt of a blood transfusion or blood products, including immunoglobulins * Participation in another interventional study within 14 days before the first study vaccination or during the study * Receipt…